Stay updated with breaking news from Biodesix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Wall Street brokerages expect that Biodesix, Inc. (NASDAQ:BDSX – Get Rating) will report $8.60 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Biodesix’s earnings, with estimates ranging from $8.11 million to $8.90 million. Biodesix reported sales of $11.89 million during the same quarter last year, which […]
Biodesix, Inc. (NASDAQ:BDSX – Get Rating) has received an average recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among […]
03.06.2022 - Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (MRD) test as a part of a master sponsored research ... Seite 1
01.06.2022 - Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference ...
Equities analysts expect that Biodesix, Inc. (NASDAQ:BDSX – Get Rating) will report sales of $8.60 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Biodesix’s earnings, with the lowest sales estimate coming in at $8.11 million and the highest estimate coming in at $8.90 million. Biodesix reported sales of $11.89 […]